Hugel Inc
145020
Company Profile
Business description
Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. Geographically, it has a presence in the U.S., Australia, Canada, Taiwan, China, Hong Kong, Singapore, and Thailand.
Contact
23, Geodudanji 1-gil
Dongnae-myeon
Gangwon-do
Chuncheon
KORT: +82 338155200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
625
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,080.80 | 68.20 | 0.76% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,342.56 | 132.54 | -0.25% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,775.21 | 65.04 | 0.47% |
| S&P 500 | 7,720.39 | 23.59 | -0.30% |
| S&P/ASX 200 | 8,961.30 | 69.50 | 0.78% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |